非小细胞肺癌VEGFR-2与XAGE-1b基因表达相关性研究

Correlation between VEGFR-2 and XAGE-1b Gene Expressions in Non-Small Cell Lung Cancer

目的探讨非小细胞肺癌中血管内皮生长因子受体-2(VEGFR-2)与肿瘤-睾丸抗原XAGE-1b基因表达的相关性。方法从30例非小细胞肺癌患者肿瘤组织中提取总RNA、RT-PCR反应扩增XAGE-1b基因、定量RT-PCR检测VEGFR-2表达水平,分析二者表达的相关性以及与临床特征的相关性。结果 30例患者中,XAGE-1b表达阳性率为40%,61.1%的腺癌表达XAGE-1b,远高于非腺癌的8.3%(χ2=6.302,P=0.012)。XAGE-1b与VEGFR-2表达水平呈正相关(r=0.546,P=0.002),XAGE-1b阳性患者的VEGFR-2表达水平偏高。多元回归分析显示,病理类型(比值比0.072,95%可信区间0.007～0.785,P=0.031)和VEGFR-2表达水平(比值比14.765,95%可信区间1.274～171.144,P=0.031)是XAGE-1b表达的影响因素。XAGE-1b表达阳性与阴性、VEGFR-2表达高与低患者的生存时间差异均无统计学意义(Log-rankP=0.416、P=0.384)。结论非小细胞肺癌中VEGFR-2与XAGE-1b基因表达呈正相关,XAGE-1b表达阳性并且VEGFR-2高表达的患者可能是免疫疗法与抗血管生成疗法联合治疗的合适人群。

Objective To explore the correlation between vascular endothelial growth factor receptor-2 （VEGFR-2） and cancer-testis antigens XAGE-1b gene expressions in non-small cell lung cancer （NSCLC）. Methods Tumor tissues were obtained from 30 patients with NSCLC and the total RNA was extracted for RT-PCR. Full-length XAGE-1b gene was amplified by RT-PCR and VEGFR-2 mRNA expression level was evaluated by quantitative real-time PCR. The correlation between VEGFR-2 and XAGE-1b gene expressions and the association between gene expressions and clinical characteristics were analyzed. Results In the 30 tumor tissue specimens, the expression rate of XAGE-1b gene was 40%. XAGE-lb expression was associated with pathology （adenearcinoma vs. non- adencarcinoma： 61.1% vs. 8.3%,χ2=6.302,P=0.012）. There was positive correlation between XAGE-lb and VEGFR-2 expressions （r=0.546, P=0.002）. Pathology （ OR=0.072,95%CI=0.007-0.785, P=O.031 ） and VEGFR-2 expression level （OR= 14.765,95 %CI= 1.274-171.144,P=0.031 ）were influential factors for XAGE-1b expression. There were no significant difference in the overall survival between the patients with positive and negative XAGE-1b or with high level and low level VEGFR-2 （Log-rank P=0.416 and 0.384）. Conclusions Patients with NSCLC whose tumor was XAGE-1b positive and VEGFR-2 high expression might be appropriate population for combination therapy of antiangiogenic treatment with immunotherapy.